 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for MSMB |
 Gene summary |
| Basic gene information | Gene symbol | MSMB |
| Gene name | microseminoprotein, beta- | |
| Synonyms | HPC13|IGBF|MSP|MSPB|PN44|PRPS|PSP|PSP-94|PSP57|PSP94 | |
| Cytomap | UCSC genome browser: 10q11.2 | |
| Type of gene | protein-coding | |
| RefGenes | NM_002443.3, NM_138634.2, | |
| Description | beta-microseminoproteinimmunoglobulin binding factorprostate secreted seminal plasma proteinprostate secretory protein of 94 amino acidsseminal plasma beta-inhibin | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 157145 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000263639 | ||
| HPRD : 01143 | ||
| Vega : OTTHUMG00000188315 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_MSMB | |
| BioGPS: 4477 | ||
| Pathway | NCI Pathway Interaction Database: MSMB | |
| KEGG: MSMB | ||
| REACTOME: MSMB | ||
| Pathway Commons: MSMB | ||
| Context | iHOP: MSMB | |
| ligand binding site mutation search in PubMed: MSMB | ||
| UCL Cancer Institute: MSMB | ||
| Assigned class in TissGDB* | A | |
| Included tissue-specific gene expression resources | HPA,TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Prostate | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | PRAD | |
| Reference showing the relevant tissue of MSMB | Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC, Freedman ML. PLoS Genet. 2010 Nov 11;6(11):e1001204. doi: 10.1371/journal.pgen.1001204. (pmid:21085629) go to article | |
| Description by TissGene annotations | Cancer gene TissgsKTS CNV lost TissGeneKTS | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID |
| Top |
| TissGeneExp for MSMB |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| BRCA | 0.789595682 | -1.144174494 | 1.933770175 | 1.29E-07 | 3.85E-07 |
| HNSC | -0.275656113 | 1.388522956 | -1.66417907 | 0.0188 | 0.042089552 |
| Top |
| TissGene-miRNA for MSMB |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for MSMB |
| TissGeneSNV for MSMB |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.I48V | LUSC | 1 |
| p.W112* | SKCM | 1 |
| p.P103S | SKCM | 1 |
| p.Q68X | SKCM | 1 |
| p.V73A | STAD | 1 |
| p.G43* | UCEC | 1 |
| p.E64K | COAD | 1 |
| p.G32V | THYM | 1 |
| p.R64K | SKCM | 1 |
| p.C60W | UCEC | 1 |
| p.L4F | SKCM | 1 |
| p.N76S | OV | 1 |
| p.K89* | LUAD | 1 |
| p.W52R | LUAD | 1 |
| p.T67I | LIHC | 1 |
| p.V109D | OV | 1 |
| p.E51Q | LUAD | 1 |
| p.G43R | SKCM | 1 |
| p.Q68* | SKCM | 1 |
| p.R66K | SKCM | 1 |
| p.S50* | LUAD | 1 |
| Top |
| TissGeneCNV for MSMB |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for MSMB |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Chimerdb3.0 | FusionScan | PRAD | TCGA-XK-AAIV-01A | ANKRD22-MSMB | In-Frame | chr10:90585794 | chr10:51555730 |
| TCGAfusionPortal | PRADA | BRCA | TCGA-A2-A25D-01A | KCNMA1-MSMB | In-frame | Chr10:78869931 | Chr10:51555731 |
| TCGAfusionPortal | PRADA | LUSC | TCGA-77-6843-01A | MARCH8-MSMB | In-frame | Chr10:45984815 | Chr10:51555731 |
| Top |
| TissGeneNet for MSMB |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| MSMB, HNF4A (tumor) | MSMB, HNF4A (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| MSMB, HNF4A (tumor) | MSMB, HNF4A (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| MSMB, HNF4A (tumor) | MSMB, HNF4A (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| MSMB, HNF4A (tumor) | MSMB, HNF4A (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| MSMB, HNF4A (tumor) | MSMB, HNF4A (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| MSMB, HNF4A (tumor) | MSMB, HNF4A (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| MSMB, HNF4A (tumor) | MSMB, HNF4A (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| MSMB, HNF4A (tumor) | MSMB, HNF4A (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| MSMB, HNF4A (tumor) | MSMB, HNF4A (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| MSMB, HNF4A (tumor) | MSMB, HNF4A (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| MSMB, HNF4A (tumor) | MSMB, HNF4A (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| MSMB, HNF4A (tumor) | MSMB, HNF4A (normal) |
 |  |
| Top |
| TissGeneProg for MSMB |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for MSMB |
| TissGeneDrug for MSMB |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for MSMB |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0376358 | Malignant neoplasm of prostate | 56 | BeFree,GAD,GWASCAT,MGD |
| umls:C0024530 | Malaria | 45 | BeFree |
| umls:C0600139 | Prostate carcinoma | 41 | BeFree |
| umls:C0033578 | Prostatic Neoplasms | 12 | BeFree,CTD_human,GAD,LHGDN |
| umls:C0024623 | Malignant neoplasm of stomach | 5 | BeFree |
| umls:C0027627 | Neoplasm Metastasis | 5 | BeFree |
| umls:C0699791 | Stomach Carcinoma | 5 | BeFree |
| umls:C0006142 | Malignant neoplasm of breast | 4 | BeFree |
| umls:C0024535 | Malaria, Falciparum | 4 | BeFree |
| umls:C0275524 | Coinfection | 4 | BeFree |
| umls:C0302592 | Cervix carcinoma | 4 | BeFree |
| umls:C0949664 | Tauopathies | 4 | BeFree |
| umls:C0002736 | Amyotrophic Lateral Sclerosis | 3 | BeFree |
| umls:C0007847 | Malignant tumor of cervix | 3 | BeFree |
| umls:C0009402 | Colorectal Carcinoma | 3 | BeFree |
| umls:C0038868 | Progressive supranuclear palsy | 3 | BeFree |
| umls:C0596263 | Carcinogenesis | 3 | BeFree |
| umls:C0678222 | Breast Carcinoma | 3 | BeFree |
| umls:C1527249 | Colorectal Cancer | 3 | BeFree |
| umls:C0002312 | alpha-Thalassemia | 2 | BeFree |
| umls:C0007103 | Malignant neoplasm of endometrium | 2 | BeFree |
| umls:C0007124 | Noninfiltrating Intraductal Carcinoma | 2 | BeFree |
| umls:C0017638 | Glioma | 2 | BeFree |
| umls:C0029925 | Ovarian Carcinoma | 2 | BeFree |
| umls:C0036341 | Schizophrenia | 2 | BeFree |
| umls:C0085084 | Motor Neuron Disease | 2 | BeFree |
| umls:C0242723 | Parasitemia | 2 | BeFree |
| umls:C0346647 | Malignant neoplasm of pancreas | 2 | BeFree |
| umls:C0476089 | Endometrial Carcinoma | 2 | BeFree |
| umls:C1140680 | Malignant neoplasm of ovary | 2 | BeFree |
| umls:C1168401 | Squamous cell carcinoma of the head and neck | 2 | BeFree |
| umls:C1456873 | alpha^+^ Thalassemia | 2 | BeFree |
| umls:C1704272 | Benign Prostatic Hyperplasia | 2 | BeFree |
| umls:C1862939 | AMYOTROPHIC LATERAL SCLEROSIS 1 | 2 | BeFree |
| umls:C1883486 | Uterine Corpus Cancer | 2 | BeFree |
| umls:C2239176 | Liver carcinoma | 2 | BeFree |
| umls:C0001418 | Adenocarcinoma | 1 | BeFree |
| umls:C0007095 | Carcinoid Tumor | 1 | BeFree |
| umls:C0007131 | Non-Small Cell Lung Carcinoma | 1 | BeFree |
| umls:C0007134 | Renal Cell Carcinoma | 1 | BeFree |
| umls:C0014175 | Endometriosis | 1 | BeFree |
| umls:C0017636 | Glioblastoma | 1 | BeFree |
| umls:C0019360 | Herpes zoster disease | 1 | BeFree |
| umls:C0023267 | Fibroid Tumor | 1 | BeFree |
| umls:C0024305 | Lymphoma, Non-Hodgkin | 1 | BeFree |
| umls:C0025202 | melanoma | 1 | BeFree |
| umls:C0026946 | Mycoses | 1 | BeFree |
| umls:C0030305 | Pancreatitis | 1 | BeFree |
| umls:C0030354 | Papilloma | 1 | BeFree |
| umls:C0031099 | Periodontitis | 1 | BeFree |
| umls:C0032002 | Pituitary Diseases | 1 | BeFree |
| umls:C0032897 | Prader-Willi Syndrome | 1 | BeFree |
| umls:C0032927 | Precancerous Conditions | 1 | BeFree |
| umls:C0033575 | Prostatic Diseases | 1 | BeFree |
| umls:C0037054 | Sickle Cell Trait | 1 | BeFree |
| umls:C0039483 | Giant Cell Arteritis | 1 | BeFree |
| umls:C0039614 | Tetanus | 1 | BeFree |
| umls:C0042133 | Uterine Fibroids | 1 | BeFree |
| umls:C0042769 | Virus Diseases | 1 | BeFree |
| umls:C0042798 | Low Vision | 1 | BeFree |
| umls:C0042961 | Intestinal Volvulus | 1 | BeFree |
| umls:C0079745 | Lymphoma, Large-Cell, Follicular | 1 | BeFree |
| umls:C0149782 | Squamous cell carcinoma of lung | 1 | BeFree |
| umls:C0149911 | Humoral hypercalcemia of malignancy (disorder) | 1 | BeFree |
| umls:C0149925 | Small cell carcinoma of lung | 1 | BeFree |
| umls:C0162557 | Liver Failure, Acute | 1 | BeFree |
| umls:C0162635 | Angelman Syndrome | 1 | BeFree |
| umls:C0178874 | Tumor Progression | 1 | BeFree |
| umls:C0206754 | Neuroendocrine Tumors | 1 | BeFree |
| umls:C0235974 | Pancreatic carcinoma | 1 | BeFree |
| umls:C0242379 | Malignant neoplasm of lung | 1 | BeFree |
| umls:C0275522 | Asymptomatic Infections | 1 | BeFree |
| umls:C0278488 | Carcinoma breast stage IV | 1 | BeFree |
| umls:C0279626 | Squamous cell carcinoma of esophagus | 1 | BeFree |
| umls:C0338656 | Impaired cognition | 1 | BeFree |
| umls:C0472762 | Alpha trait thalassemia | 1 | BeFree |
| umls:C0483368 | Human anaplasmosis due to Anaplasma phagocytophilum | 1 | BeFree |
| umls:C0585362 | Squamous cell carcinoma of mouth | 1 | BeFree |
| umls:C0677948 | Stage II Colorectal Cancer | 1 | BeFree |
| umls:C0684249 | Carcinoma of lung | 1 | BeFree |
| umls:C0686619 | Secondary malignant neoplasm of lymph node | 1 | BeFree |
| umls:C0740380 | Varicella zoster | 1 | BeFree |
| umls:C0751072 | Frontotemporal Lobar Degeneration | 1 | BeFree |
| umls:C0936223 | Metastatic Prostate Carcinoma | 1 | BeFree |
| umls:C0949541 | Hurthle Cell Tumor | 1 | BeFree |
| umls:C1335302 | Pancreatic Ductal Adenocarcinoma | 1 | BeFree |
| umls:C1378050 | Oncocytic Neoplasm | 1 | BeFree |
| umls:C1510502 | Oxyphilic Adenoma | 1 | BeFree |
| umls:C1562061 | Microspherophakia | 1 | BeFree |
| umls:C2931456 | Prostate cancer, familial | 1 | BeFree,ORPHANET |
| umls:C2939465 | Deficiency of glucose-6-phosphate dehydrogenase | 1 | BeFree |
| umls:C3146252 | Stage II Colorectal Cancer AJCC v7 | 1 | BeFree |
| umls:C3826128 | Infection in children | 1 | BeFree |
| umls:C2677821 | Prostate Cancer, Hereditary, 13 | 0 | CLINVAR,CTD_human |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |